Clinical Trials Logo

Filter by:
NCT ID: NCT05190640 Completed - Anxiety Clinical Trials

Study to Evaluate the Efficacy of Asystems' Complete Calm Supplementation on Sleep Quality and Duration, Anxiety, and Stress

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

This is an open-label observational single-arm clinical trial to study the efficacy of a commercial dietary supplement and its effect on sleep quality, sleep duration, anxiety, mood, and stress.

NCT ID: NCT05190419 Completed - Psoriasis Clinical Trials

Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

IASOS
Start date: December 30, 2021
Phase: Phase 2
Study type: Interventional

This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe plaque-type psoriasis. The purpose of the study is to assess the effect of orismilast modified release in moderate-to-severe plaque-type psoriasis and assess the safety aspects of these 3 different doses.The patients will receive an oral treatment of either orismilast modified release tablets or placebo tablets 2 times a day for 16 weeks.

NCT ID: NCT05190354 Completed - Amputation Clinical Trials

Post Market Clinical Protocol - Xtremity Polymer Prosthetic Socket System

Start date: November 16, 2021
Phase: N/A
Study type: Interventional

Single-arm, prospective multi-center study assessing user preference of the Xtremity prosthetic socket in below the knee amputation prostheses.

NCT ID: NCT05190159 Completed - Ankle Injuries Clinical Trials

Monster Screw System Post-Market Clinical Follow-Up Study

Start date: January 26, 2022
Phase:
Study type: Observational

Post-market clinical follow-up study on the Monster Screw System

NCT ID: NCT05190120 Completed - Clinical trials for Anterior Cruciate Ligament Tear

Adductor Canal Block Versus Femoral Block on Pain and Quadriceps Strength

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effects of a femoral nerve block vs. an adductor canal block on pain and quadriceps muscle strength for knee arthroscopy surgery.

NCT ID: NCT05189340 Completed - Clinical trials for Educational Activities

Development of Discharge Education Video for Solid Organ Transplant Recipients

Start date: April 11, 2022
Phase: N/A
Study type: Interventional

Audiovisual teaching aids can play a significant role for the retention of new material and help overcome barriers such as the physical presence or time restrictions of an instructor. In a clinical setting, multimedia health education can offer an advantage over traditional didactic teaching by engaging patients through visual content and unlimited accessibility. A critical factor to long-term survival of solid organ transplant recipients is compliance to post-transplantation medication and follow-up patient care. Transplant pharmacists serve on multidisciplinary care teams as the medication experts that provide discharge education to recipients and caregivers often at the bedside. The adoption of digital multimedia content for patient education can increase engagement of diverse learning styles while simultaneously reducing potential time conflicts in hospital practice. This study contributes to the literature by assessing the effectiveness of discharge education video(s) on patient satisfaction and knowledge levels which are currently limited.

NCT ID: NCT05189275 Completed - Healthy Clinical Trials

Cannabidiol and Focus Study (CBD-Focus)

CBD-Focus
Start date: January 10, 2022
Phase: N/A
Study type: Interventional

Cannabidiol (CBD), a non-psychoactive hemp derivative, is an attractive therapeutic target, and is most supported by the scientific community as an antiepileptic, anxiolytic, and antipsychotic. Additionally, CBD may cause alterations in aspects of health and fitness, fatigue, stress, calmness, quality of life, cognitive function, ability to maintain focus, sleep quantity, and sleep quality. Cannabidiol may be associated with alterations in inflammatory response in the human body, which has implications in both healthy and diseased populations. Natural killers cells (NKC) play a vital role in maintain your body's defenses and are an essential component of your immune system. In humans, NKC contain the highest concentrations of receptors associated with the endocannabinoid system and CBD. Human models have demonstrated that CBD use increases the percentage of NKC in peripheral blood. However, similar models found that CBD administration inhibits markers of NKC cytotoxic function, a beneficial cellular mechanism used to prevent malignant cell transformation and viral infection. The overarching goal of this investigation is to determine the effects of an 8-week CBD intervention on measures of fatigue, stress, calmness, quality of life, cognitive function, focus, health and fitness, and sleep quantity, and sleep quality. In addition, this study will explore a potential CBD mechanism of action with a focus on biomarkers of neural health, inflammation, liver health, kidney health, as well as NKC number and function.

NCT ID: NCT05189080 Completed - Child Health Clinical Trials

Twilio Well-Child Visit Pilot Open Trial

Start date: December 17, 2021
Phase: N/A
Study type: Interventional

This project will use Twilio as a platform for a text messaging campaign to implement timely follow up with parents/guardians of children ages 0 to 17 years who have no-showed for WCVs. The first phase of the study will be an open trial to assess feasibility and acceptability of three different reminder messages, analyze preliminary data, and collect feedback from participants using interviews to identify the top one or two performing messages. Each reminder message will at minimum direct parents/guardians to reschedule by phone or by the patient portal. These findings will be used to conduct the second phase of the study, a randomized controlled trial.

NCT ID: NCT05188521 Completed - Clinical trials for Cutaneous Lichen Planus

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

Start date: January 11, 2022
Phase: Phase 2
Study type: Interventional

This research study is evaluating the safety and efficacy of Baricitinib in treating Cutaneous Lichen Planus (LP).

NCT ID: NCT05188261 Completed - Healthy Volunteers Clinical Trials

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

Start date: January 18, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human study to evaluate the safety and tolerability of single ascending doses of IW-3300. The study drug will be administered rectally as a low-volume (20 mL) enema. Study participants will be randomized in a 3:1 ratio to receive a single dose of IW-3300 or placebo. Up to 5 different doses of IW-3300 will be studied. Safety reviews will be conducted before proceeding to each higher dose.